Klump Michael A 4

Accession 0000899243-19-013098

CIK 0001175680other

View on SEC.gov Company Profile

Filed

May 9, 8:00 PM ET

Accepted

May 10, 5:25 PM ET

Size

47.4 KB

Accession

0000899243-19-013098

Insider Transaction Report

Form 4

Period: 2019-05-08

CytoDyn Inc.CYDY

Klump Michael A

Director

Transactions

Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−500,000→ 0 total(indirect: See Footnote)
Exercise: $0.30From: 2019-01-08Exp: 2024-01-08→ Common Stock (500,000 underlying)
Award
Warrant (Right to Buy)
2019-05-08+66,667→ 66,667 total(indirect: By Trust)
Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (66,667 underlying)
Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−125,000→ 0 total
Exercise: $1.35From: 2016-04-26Exp: 2021-04-26→ Common Stock (125,000 underlying)
Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+1,933,333$773,333→ 9,967,853 total(indirect: See Footnote)
Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+125,000$50,000→ 125,000 total
Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−125,000→ 0 total
Exercise: $0.40From: 2016-04-26Exp: 2021-04-26→ Common Stock (125,000 underlying)
Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+1,000,000$400,000→ 8,034,520 total(indirect: See Footnote)
Exercise/Conversion
Common Stock
2019-05-08$0.30/sh+500,000$150,000→ 10,467,853 total(indirect: See Footnote)
Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+66,667$26,667→ 66,667 total(indirect: By Trust)
Award
Common Stock
2019-05-08+1,716,666→ 12,184,519 total(indirect: See Footnote)
Award
Common Stock
2019-05-08+33,333→ 100,000 total(indirect: By Trust)
Award
Common Stock
2019-05-08+62,500→ 187,500 total
Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−1,000,000→ 0 total(indirect: See Footnote)
Exercise: $0.75From: 2018-02-16Exp: 2023-02-16→ Common Stock (1,000,000 underlying)
Award
Warrant (Right to Buy)
2019-05-08+1,000,000→ 1,000,000 total(indirect: See Footnote)
Exercise: $0.40From: 2018-02-16Exp: 2023-02-16→ Common Stock (1,000,000 underlying)
Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−1,000,000→ 0 total(indirect: See Footnote)
Exercise: $0.40From: 2018-02-16Exp: 2023-02-16→ Common Stock (1,000,000 underlying)
Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−1,933,333→ 0 total(indirect: See Footnote)
Exercise: $1.00From: 2016-12-12Exp: 2021-12-12→ Common Stock (1,933,333 underlying)
Award
Warrant (Right to Buy)
2019-05-08+1,933,333→ 1,933,333 total(indirect: See Footnote)
Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (1,933,333 underlying)
Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−1,933,333→ 0 total(indirect: See Footnote)
Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (1,933,333 underlying)
Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−66,667→ 0 total(indirect: By Trust)
Exercise: $1.00From: 2016-12-12Exp: 2021-12-12→ Common Stock (66,667 underlying)
Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−66,667→ 0 total(indirect: By Trust)
Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (66,667 underlying)
Award
Warrant (Right to Buy)
2019-05-08+125,000→ 125,000 total
Exercise: $0.40From: 2016-04-26Exp: 2021-04-26→ Common Stock (125,000 underlying)

Footnotes (2)

[F1]The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein.
[F2]On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

CytoDyn Inc.

CIK 0001175680

→

Entity typeother

Related Parties

filerCIK 0001748882

Filing Metadata

Form type: 4
Filed: May 9, 8:00 PM ET
Accepted: May 10, 5:25 PM ET
Size: 47.4 KB

View on SEC.gov